Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Appendix B: Panel Roster and Financial Disclosures


Last Updated: March 1, 2018; Last Reviewed: March 1, 2018

Human Papillomavirus Disease
Member Financial Disclosure
Company Relationship
Brown, Darron Indiana University School of Medicine Merck Advisory Board, Honoraria, Patent, Speaker’s Bureau
PDS, Inc. Advisory Board
Cu-Uvin, Susan* Brown University Gilead Advisory Board
Dunne, Eileen Centers for Disease Control and Prevention None N/A
Einstein, Mark Rutgers New Jersey Medical School Baxalta Research Support
Becton-Dickinson Research Support
Eli Lilly Research Support
Inovio Advisory Board, Research Support, Travel Support
Natera Consultant
Papivax Consultant
PDS, Inc. Consultant, Research Support, Travel Support
Photocure Consultant, Research Support, Travel Support
Roche Molecular Diagnostics Advisory Board, Travel Support
Massad, L. Stewart Washington University School of Medicine None N/A
Moscicki, Anna Barbara
University of California, Los Angeles
Inovio Advisory Board
Merck Advisory Board, Honoraria
Palefsky, Joel University of California, San Francisco Aura Biosciences Advisory Board, Travel Support
Hologic Research Support
Merck Advisory Board, Consultant, Research Support, Travel Support
Pharmajet Advisory Board
Qiagen Consultant
Stier, Elizabeth Boston University Medical Center None N/A
Strickler, Howard Albert Einstein College of Medicine BD Sciences, Arbor Vita, MTM/Roche, Norchip AS These companies providing free testing in a study of molecular methods for cervical cancer screening in HIV+ women.
Wilkin, Timothy Weill Cornell Medical College GlaxoSmithKline/ViiV Consultant, Research Support
Johnson & Johnson Spouse owns stock.
*Group lead

Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from March 1, 2017, through March 1, 2018.

Download Guidelines